Phase 4 N=398 CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
Patient Adherence · HIV Seronegativity
Primary: Adherence to PrEP — 85.6; 91.7; 81.6; 83.4 % participants with > 719 fmol/punch
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema
Diabetic Retinopathy · Macula Edema
Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer
Phase 4 N=40 A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo
Posterior Cervical Decompression and Fusion
Primary: Changes Motor Evoked Potentials (MEPs) Amplitude at 3 Minutes — 652.9; 20.6; 2153.4; 55 micro volts — p=<0.01
Phase 4 N=16 Bioequivalence of Ethylenediamine Dihydrochloride Study
Allergic Contact Dermatitis
Primary: Number of Participants With Positive Reactions to Ethylenediamine Dihydrochloride in MC (Methylcellulose) and Ethylenediamine Dihydrochloride in PVP…
Phase 4 N=136 Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
HIV Prevention
Primary: Adherence to PrEP — 22; 11; 30; 54 Participants
Phase 4 N=198 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
Heroin Dependence · Opioid-Related Disorders
Primary: Time-to-Relapse: XRNTX vs. ETAU Following Release From Jail — 8.6; 5.9 Weeks
Phase 4 N=43 Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
Adverse Reaction to Spinal Anesthetic · Maternal Care for Cervical Incompetence
Primary: Time to Resolution of Motor Block — 109; 112 minutes
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Phase 4 N=62 Quality of Recovery After Reversal With Neostigmine or Sugammadex.
Incomplete Reversal of Neuromuscular Block
Primary: Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes — -700; -862 mL
Phase 4 N=271 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Macular Degeneration
Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162
Phase 4 N=83 Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
Type 2 Diabetes Mellitus
Primary: Normoglycemia on Therapy — 14; 1; 19; 1 Participants
Phase 4 N=150 Tranexamic Acid in Knee Joint Surgery
Osteoarthritis
Primary: Blood Loss — 1090; 716; 746 mls — p=<0.05
Phase 4 N=18 Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension
Prolonged Second Stage of Labor
Primary: Number of Participants With Uterine Extension of Hysterotomy — 3; 4 Participants
Phase 4 N=98 Buffered Lidocaine in Paracervical Blocks
Pain
Primary: Injection Pain — 44.5; 30 units on a scale
Phase 4 N=206 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
Hidradenitis Suppurativa (HS)
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 34.0; 47.6 percentage of participants — p==0.049